scholarly journals TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR

Oncotarget ◽  
2014 ◽  
Vol 5 (23) ◽  
pp. 12428-12439 ◽  
Author(s):  
Kun Wang ◽  
Tiantian Liu ◽  
Nan Ge ◽  
Li Liu ◽  
Xiaotian Yuan ◽  
...  
Keyword(s):  
Distant Metastases ◽  
Urinary Biomarkers ◽  
Upper Tract ◽  
Urothelial Carcinomas ◽  
Tert Promoter ◽  
Tert Promoter Mutations ◽  
Promoter Mutations

scholarly journals TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas

Oncotarget ◽  
2014 ◽  
Vol 5 (7) ◽  
pp. 1829-1836 ◽  
Author(s):  
Kun Wang ◽  
Tiantian Liu ◽  
Li Liu ◽  
Jikai Liu ◽  
Cheng Liu ◽  
...  
Keyword(s):  
Renal Cell ◽  
Renal Cell Carcinomas ◽  
Upper Tract ◽  
Urothelial Carcinomas ◽  
Tert Promoter ◽  
Tert Promoter Mutations ◽  
Promoter Mutations

scholarly journals TERT Promoter Mutations and TERT mRNA but Not FGFR3 Mutations Are Urinary Biomarkers in Han Chinese Patients With Urothelial Bladder Cancer

2015 ◽  
Vol 20 (3) ◽  
pp. 263-269 ◽  
Author(s):  
Kun Wang ◽  
Tiantian Liu ◽  
Cheng Liu ◽  
Yan Meng ◽  
Xiaotian Yuan ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Han Chinese ◽  
Urinary Biomarkers ◽  
Chinese Patients ◽  
Urothelial Bladder Cancer ◽  
Tert Promoter ◽  
Tert Promoter Mutations ◽  
Urothelial Bladder ◽  
Promoter Mutations ◽  
Fgfr3 Mutations

Prognostic significance of TERT promoter mutations in follicular cell-derived thyroid carcinomas

2014 ◽  
Author(s):  
Miguel Melo ◽  
Rocha Adriana Gaspar da ◽  
Joao Vinagre ◽  
Rui Batista ◽  
Joana Peixoto ◽  
...  
Keyword(s):  
Prognostic Significance ◽  
Follicular Cell ◽  
Thyroid Carcinomas ◽  
Tert Promoter ◽  
Tert Promoter Mutations ◽  
Promoter Mutations

In papillary thyroid cancer TERT promoter mutations have a worst impact on outcome than BRAF mutations

2015 ◽  
Author(s):  
Marina Muzza ◽  
Carla Colombo ◽  
Maria Carla Proverbio ◽  
Stefania Rossi ◽  
Delfina Tosi ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Papillary Thyroid ◽  
Braf Mutations ◽  
Tert Promoter ◽  
Tert Promoter Mutations ◽  
Promoter Mutations

TERT promoter mutations in pancreatic endocrine tumours are frequent in tumours from patients with hereditary syndromes

2016 ◽  
Author(s):  
Joao Vinagre ◽  
Joana Nabais ◽  
Jorge Pinheiro ◽  
Rui Batista ◽  
Rui Oliveira ◽  
...  
Keyword(s):  
Endocrine Tumours ◽  
Hereditary Syndromes ◽  
Tert Promoter ◽  
Tert Promoter Mutations ◽  
Pancreatic Endocrine Tumours ◽  
Promoter Mutations

scholarly journals Human TERT promoter mutations as a prognostic biomarker in glioma

2021 ◽  
Vol 147 (4) ◽  
pp. 1007-1017
Author(s):  
Branka Powter ◽  
Sarah A. Jeffreys ◽  
Heena Sareen ◽  
Adam Cooper ◽  
Daniel Brungs ◽  
...  
Keyword(s):  
Clinical Utility ◽  
Nucleotide Polymorphism ◽  
Liquid Biopsies ◽  
Single Nucleotide ◽  
Tert Promoter ◽  
Tert Promoter Mutations ◽  
Potential Clinical Utility ◽  
Promoter Mutations ◽  
The Relationship ◽  
Potential Use

AbstractThe TERT promoter (pTERT) mutations, C228T and C250T, play a significant role in malignant transformation by telomerase activation, oncogenesis and immortalisation of cells. C228T and C250T are emerging as important biomarkers in many cancers including glioblastoma multiforme (GBM), where the prevalence of these mutations is as high as 80%. Additionally, the rs2853669 single nucleotide polymorphism (SNP) may cooperate with these pTERT mutations in modulating progression and overall survival in GBM. Using liquid biopsies, pTERT mutations, C228T and C250T, and other clinically relevant biomarkers can be easily detected with high precision and sensitivity, facilitating longitudinal analysis throughout therapy and aid in cancer patient management.In this review, we explore the potential for pTERT mutation analysis, via liquid biopsy, for its potential use in personalised cancer therapy. We evaluate the relationship between pTERT mutations and other biomarkers as well as their potential clinical utility in early detection, prognostication, monitoring of cancer progress, with the main focus being on brain cancer.

scholarly journals TERT Promoter Mutations and the 8th Edition TNM Classification in Predicting the Survival of Thyroid Cancer Patients

Cancers ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 648
Author(s):  
Jun Park ◽  
Sungjoo Lee ◽  
Kyunga Kim ◽  
Hyunju Park ◽  
Chang-Seok Ki ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Prognostic Factor ◽  
Histologic Type ◽  
Stage At Diagnosis ◽  
Tert Promoter ◽  
Tert Promoter Mutations ◽  
Specific Mortality ◽  
Cancer Specific Mortality ◽  
Promoter Mutations ◽  
8Th Edition

Our research group has previously shown that the presence of TERT promoter mutations is an independent prognostic factor, by applying the TERT mutation status to the variables of the AJCC 7th edition. This study aimed to determine if TERT mutations could be independent predictors of thyroid cancer-specific mortality based on the AJCC TNM 8th edition, with long-term follow-up. This was a retrospective study of 393 patients with pathologically confirmed differentiated thyroid carcinoma (DTC) after thyroidectomy at a tertiary Korean hospital from 1994 to 2004. The thyroid cancer-specific mortality rate was 6.9% (5.2% for papillary and 15.2% for follicular cancers). TERT promoter mutations were identified in 10.9% (43/393) of DTC cases (9.8% of papillary and 16.7% of follicular cancer) and were associated with older age (p < 0.001), the presence of extrathyroidal invasion (p < 0.001), distant metastasis (p = 0.001), and advanced stage at diagnosis (p < 0.001). The 10-year survival rate in mutant TERT was 67.4% for DTC patients (vs. 98% for wild-type; adjusted hazard ratio (HR) of 9.93, (95% CI: 3.67–26.90)) and 75% for patients with papillary cancer (vs. 99%; 18.55 (4.83–71.18)). In addition, TERT promoter mutations were related to poor prognosis regardless of histologic type (p < 0.001 for both papillary and follicular cancer) or initial stage (p < 0.001, p = 0.004, and p = 0.086 for stages I, II, and III and IV, respectively). TERT promoter mutations comprise an independent poor prognostic factor after adjusting for the clinicopathological risk factors of the AJCC TNM 8th edition, histologic type, and each stage at diagnosis, which could increase prognostic predictability for patients with DTC.

scholarly journals Preoperative detection of the TERT promoter mutations in papillary thyroid carcinomas

2021 ◽  
Author(s):  
Tomoe Nakao ◽  
Michiko Matsuse ◽  
Vladimir Saenko ◽  
Tatiana Rogounovitch ◽  
Aya Tanaka ◽  
...  
Keyword(s):  
Papillary Thyroid ◽  
Thyroid Carcinomas ◽  
Tert Promoter ◽  
Tert Promoter Mutations ◽  
Promoter Mutations
Sign in / Sign up

Export Citation Format

Share Document